Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
Outline of Final Research Achievements |
In cancer-bearing model mice, the abundance ratio of B220-positive and CD4-positive cells in peripheral blood changes correlate with increasing tumor volume. It also clarified the changes in the repertoire of the variable region of antibody genes (BCRs) and the α chain and β chain of T cell receptor genes (TCRs). Furthermore, to verify their binding specificity, we constructed the single-chain antibody (scFv-Fc) and scTCR-Fc. In the future, we plan to continue building a platform to utilize the obtained variable part as a new molecular-targeted drug discovery drug.
|